Ryan Joseph Sullivan
Harvard University · 1,120 works · 45,758 citations · h-index 90
Top works
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
- MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study